EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessing Therapeutic Response to Radium-223 with an Automated Bone Scan Index among Metastatic Castration-Resistant Prostate Cancer Patients: Data from Patients in the J-RAP-BSI Trial

Kazuhiro Kitajima iD, Junpei Kuyama iD, Takashi Kawahara, Tsuyoshi Suga, Tomoaki Otani, Shigeyasu Sugawara, Yumiko Kono iD, Yukihisa Tamaki, Ayumi Seko-Nitta, Yoshinobu Ishiwata iD, Kimiteru Ito iD, Akira Toriihara iD und 7 weitere

Cancers · 16.05.2023 · 15 (10) · 2784

DOI: 10.3390/cancers15102784 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 16.05.2023. Verfasst von Kazuhiro Kitajima und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Hyogo Medical University, Hyogo 663-8131, Japan. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science, and Technology of Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To evaluate the usefulness of change in the automated bone scan index (aBSI) value derived from bone scintigraphy findings as an imaging biomarker for the assessment of treatment response and survival prediction in metastatic castration-resistant prostate cancer (mCRPC) patients treated with Ra-223. This study was a retrospective investigation of a Japanese cohort of 205 mCRPC patients who received Ra-223 in 14 hospitals between July 2016 and August 2020 and for whom bone scintigraphy before and after radium-223 treatment was available. Correlations of aBSI change, with changes in the serum markers alkaline phosphatase (ALP) and prostate-specific antigen (PSA) were evaluated. Additionally, the association of those changes with overall survival (OS) was assessed using the Cox proportional-hazards model and Kaplan–Meier curve results. Of the 205 patients enrolled, 165 (80.5%) completed six cycles of Ra-223. Following treatment, ALP decline (%ALP < 0%) was noted in 72.2% (148/205), aBSI decline (%aBSI < 0%) in 52.7% (108/205), and PSA decline (%PSA < 0%) in 27.8% (57/205). Furthermore, a reduction in both aBSI and ALP was seen in 87 (42.4%), a reduction in only ALP was seen in 61 (29.8%), a reduction in only aBSI was seen in 21 (10.2%), and in both aBSI and ALP increasing/stable (≥0%) was seen in 36 (17.6%) patients. Multiparametric analysis showed changes in PSA [hazard ratio (HR) 4.30, 95% confidence interval (CI) 2.32–8.77, p < 0.0001], aBSI (HR 2.22, 95%CI 1.43–3.59, p = 0.0003), and ALP (HR 2.06, 95%CI 1.35–3.14, p = 0.0008) as significant prognostic factors for OS. For mCRPC patients treated with Ra-223, aBSI change is useful as an imaging biomarker for treatment response assessment and survival prediction.

Schlagwörter

Stichwörter der Autor:innen

223Radium-dichloridebone scintigraphycastration-resistant prostate cancer (CRPC)overall survivaltreatment response

Autor:innen und Institutionen

  • Department of Radiology, Hyogo Medical University, Hyogo 663-8131, Japan.
  • Nuclear Medicine, Chiba Cancer Center, Chiba 260-8717, Japan.
  • Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Kanagawa 232-0024, Japan.
  • Department of Radiology, Kobe City Medical Center General Hospital, Hyogo 650-0047, Japan.
  • Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8303, Japan.
  • Advanced Clinical Research Center, Fukushima Medical University, Fukushima 960-1295, Japan.

ORCID-Profile: Kazuhiro Kitajima, Junpei Kuyama, Yumiko Kono, Yoshinobu Ishiwata, Kimiteru Ito, Akira Toriihara, Shiro Watanabe, Ryohei Sasaki

Förderung

  • Ministry of Education, Culture, Sports, Science, and Technology of Japan

Zitieren

APA

Kitajima, K., Kuyama, J., Kawahara, T., Suga, T., Otani, T., Sugawara, S., Kono, Y., Tamaki, Y., Seko-Nitta, A., Ishiwata, Y., Ito, K., Toriihara, A., Watanabe, S., Hosono, M., Miyake, H., Yamamoto, S., Sasaki, R., Narita, M., & Yamakado, K. (2023). Assessing Therapeutic Response to Radium-223 with an Automated Bone Scan Index among Metastatic Castration-Resistant Prostate Cancer Patients: Data from Patients in the J-RAP-BSI Trial. Cancers, 15(10), 2784. https://doi.org/10.3390/cancers15102784

Vancouver

Kitajima K, Kuyama J, Kawahara T, Suga T, Otani T, Sugawara S, et al. Assessing Therapeutic Response to Radium-223 with an Automated Bone Scan Index among Metastatic Castration-Resistant Prostate Cancer Patients: Data from Patients in the J-RAP-BSI Trial. Cancers. 2023;15(10):2784. doi:10.3390/cancers15102784

BibTeX
@article{Kitajima2023,
  author = {Kitajima, Kazuhiro and Kuyama, Junpei and Kawahara, Takashi and Suga, Tsuyoshi and Otani, Tomoaki and Sugawara, Shigeyasu and Kono, Yumiko and Tamaki, Yukihisa and Seko-Nitta, Ayumi and Ishiwata, Yoshinobu and Ito, Kimiteru and Toriihara, Akira and Watanabe, Shiro and Hosono, Makoto and Miyake, Hideaki and Yamamoto, Shingo and Sasaki, Ryohei and Narita, Mitsuhiro and Yamakado, Koichiro},
  title = {Assessing Therapeutic Response to Radium-223 with an Automated Bone Scan Index among Metastatic Castration-Resistant Prostate Cancer Patients: Data from Patients in the J-RAP-BSI Trial},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {10},
  pages = {2784},
  doi = {10.3390/cancers15102784}
}
Kostenlos starten →